Spyre Therapeutics Inc. (SYRE)
NASDAQ: SYRE
· Real-Time Price · USD
16.93
0.07 (0.42%)
At close: Aug 15, 2025, 3:59 PM
16.95
0.12%
After-hours: Aug 15, 2025, 07:36 PM EDT
Spyre Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | 1.04M | 1.04M | 1.73M | 1.93M | 1.05M | 1.23M | 1.17M | 2.33M | 5.8M | 7.03M | 20.1M | 18.74M | 15.1M | 13.7M | n/a |
Cost of Revenue | n/a | n/a | n/a | 964K | 964K | 1.38M | 1.93M | 1.45M | 1.96M | 2.02M | 1.96M | 1.98M | 1.47M | 999K | 502K | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | 78K | 78K | 350K | n/a | -400K | -728K | -850K | 365K | 3.83M | 5.56M | 19.1M | 18.24M | 15.1M | 13.7M | n/a |
Operating Income | -222.15M | -214.36M | -208.57M | -193.23M | -156.17M | -271.27M | -242.3M | -215.55M | -215.97M | -79.15M | -84.78M | -86.06M | -87.6M | -71.88M | -65.65M | -67.98M | -65.81M | -80.67M |
Interest Income | 23.33M | 23.37M | 21.31M | 19.66M | 15.73M | 10.16M | 6.15M | 2.43M | 1.47M | 1.22M | 837K | 461K | 209K | 124K | 111K | 121K | 173K | 315K |
Pretax Income | -206.81M | -208.93M | -207.97M | -214.85M | -185.95M | -364.18M | -338.82M | -294.42M | -272.76M | -78M | -83.98M | -85.62M | -87.45M | -71.88M | -65.66M | -67.95M | -65.7M | -80.38M |
Net Income | -206.81M | -208.93M | -208.02M | -214.9M | -185.98M | -364.23M | -338.79M | -294.43M | -272.56M | -77.8M | -83.81M | -85.44M | -87.51M | -72.02M | -65.8M | -68.07M | -65.8M | -80.38M |
Selling & General & Admin | 45.15M | 44.87M | 45.78M | 49.08M | 47.01M | 47.56M | 39.95M | 30.46M | 28.33M | 23.47M | 26.57M | 28.78M | 28.64M | 27.75M | 25.78M | 26M | 25.36M | 23.74M |
Research & Development | 176.99M | 169.49M | 162.79M | 145.99M | 125.91M | 110.66M | 89.5M | 70.07M | 57.39M | 55.38M | 58.58M | 61.11M | 63.99M | 62.19M | 57.07M | 56.04M | 53.64M | 56.93M |
Other Expenses | n/a | n/a | n/a | -21.39M | -21.39M | -21.4M | -21.47M | -80K | -80K | -72K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 222.15M | 214.36M | 208.57M | 195.07M | 172.92M | 158.22M | 129.45M | 100.54M | 85.72M | 78.84M | 85.15M | 89.89M | 92.63M | 89.95M | 82.85M | 82.04M | 79M | 80.67M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 168.58M | 160.79M | 208.57M | 195.07M | 172.92M | 158.22M | 129.45M | 101.03M | 86.71M | 80.31M | 87.11M | 91.87M | 94.63M | 91.98M | 84.39M | 83.08M | 79.51M | 80.67M |
Income Tax Expense | 34K | 34K | -13K | -14K | -29K | -22K | -26K | 12K | -200K | -198K | -162K | -177K | 58K | 141K | 141K | 118K | 92K | n/a |
Shares Outstanding (Basic) | 60.7M | 60.27M | 47.03M | 50.89M | 45.32M | 36.51M | 6.9M | 4.29M | 3.82M | 3.77M | 2.61M | 3.77M | 3.29M | 2.64M | 1.97M | 2.63M | 2.63M | 2.62M |
Shares Outstanding (Diluted) | 60.7M | 60.27M | 47.03M | 50.89M | 45.32M | 36.51M | 6.9M | 4.29M | 3.82M | 3.77M | 2.61M | 3.77M | 3.29M | 2.64M | 1.97M | 2.63M | 2.63M | 2.62M |
EPS (Basic) | -2.24 | -2.5 | -3.57 | -14.71 | -22.69 | -78.62 | -82.31 | -78.22 | -73.72 | -23.72 | -28.09 | -31.25 | -34.13 | -29.94 | -27.62 | -27.08 | -26.6 | -34.11 |
EPS (Diluted) | -2.24 | -2.5 | -3.57 | -14.71 | -22.69 | -78.62 | -82.31 | -78.22 | -73.72 | -23.72 | -28.09 | -31.25 | -34.13 | -29.94 | -27.62 | -27.08 | -26.6 | -34.11 |
EBITDA | -206.93M | -214.36M | -208.57M | -195.07M | -172.92M | -157.12M | -127.6M | -98.52M | -83.53M | -77.13M | -82.82M | -84.08M | -85.6M | -69.88M | -63.79M | -66.26M | -64.36M | -79.47M |
EBIT | -148.4M | -155.83M | -203.61M | -195.07M | -172.92M | -157.53M | -128.56M | -99.97M | -85.48M | -79.15M | -84.78M | -86.06M | -87.6M | -71.88M | -65.65M | -67.98M | -65.81M | -80.67M |
Depreciation & Amortization | n/a | n/a | 43.28K | -176.72K | -216.31K | 199.69K | 704.41K | 1.41M | 1.96M | 2.02M | 1.96M | 1.98M | 2M | 2.04M | 1.89M | 1.76M | 1.48M | 1.2M |